Rhythm Pharmaceuticals Inc Bardet-Biedl and Alstrom Syndromes Phase 3 Data Corporate Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to Rhythm Pharmaceutical's conference call to discuss the Phase III data for setmelanotide in Bardet-Biedl and Alström syndromes. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, David Connolly, IR and Corporate Communications at Rhythm.
Thank you. Please go ahead, sir. Thank you, and thank you to everyone for joining us this morning as we discuss the positive top line results from our pivotal Phase III clinical trial evaluating setmelanotide in patients with Bardet-Biedl and Alström syndromes. Please note the press release issued earlier today and presentation we're using for this conference call are available online in the investors and media section of our website at rhythmtx.com.
Before we begin, I'd like to remind everybody that there will be forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |